Stoke Therapeutics/$STOK
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Stoke Therapeutics
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the bodys potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.
- Ticker
- $STOK
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 170
- Headquarters
- Bedford, United States
- Website
- www.stoketherapeutics.com
STOK Metrics
BasicAdvanced
$1.7B
-
-$3.75
-
-
Price and volume
Market cap
$1.7B
52-week high
$40.22
52-week low
$20.32
Average daily volume
1.2M
Financial strength
Current ratio
7.236
Quick ratio
6.723
Interest coverage (TTM)
-28,622.33%
Profitability
EBITDA (TTM)
-255.822
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-862.10%
Operating margin (TTM)
-913.15%
Revenue per employee (TTM)
$170,000
Management effectiveness
Return on assets (TTM)
-41.98%
Return on equity (TTM)
-73.62%
Valuation
Price to revenue (TTM)
60.47
Price to book
4.82
Price to tangible book (TTM)
4.82
Growth
Revenue change (TTM)
-86.28%
Earnings per share change (TTM)
-647.45%
3-year revenue growth (CAGR)
45.04%
3-year earnings per share growth (CAGR)
15.60%
What the Analysts think about STOK
Analyst ratings (Buy, Hold, Sell) for Stoke Therapeutics stock.
Analyst projections of the future price of Stoke Therapeutics stock.
Bulls say / Bears say
Four-year open-label extension data showed sustained seizure reductions and improvements in cognition and behaviour, supporting the possibility that zorevunersen could do more than control seizures. Some patients have received treatment for more than five years. (GlobeNewswire)
The FDA meeting gave Stoke feedback on its planned application and the analysis of cognition and behaviour in the Phase 3 trial. This regulatory alignment supports a planned NDA completion in the second half of 2027, after the expected trial readout. (Nasdaq)
Stoke reported about $420 million in cash, including proceeds from a share sale, which it expects to fund operations through a potential US launch in early 2028. Its early-stage STK-002 programme for inherited optic nerve disease also offers a potential source of value beyond its lead drug. (Stoke Therapeutics)
The long-term efficacy signal comes from open-label studies, so it does not establish that the drug works better than a control group. The pivotal, sham-controlled Phase 3 results are not expected until the third quarter of 2027, leaving a major clinical risk unresolved. (Practical Neurology)
CSF protein levels were elevated in about 94% of patients in the long-term studies, and the elevation was classed as a treatment-emergent adverse event in 59%. No serious or severe clinical effects have been linked to the elevations so far, but the finding remains a safety-monitoring concern. (GlobeNewswire)
Stoke reported a $61.6 million net loss for the second quarter and raised $65.7 million through an at-the-market share sale after quarter-end. Its cash estimate only reaches a potential launch in early 2028, so delays or higher spending could require further fundraising and dilute shareholders. (StockTitan, Stoke Therapeutics)
Data summarised monthly by Lightyear AI. Last updated on 13 Oct 2026.
STOK Financial Performance
Revenues and expenses
STOK Earnings Performance
Company profitability
Upcoming events
No upcoming events
STOK News
AllArticlesVideos
Stoke Therapeutics Q3 Earnings Call Highlights
MarketBeat2 days ago
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Business Wire2 weeks ago
Stoke Therapeutics Presents Data Supporting the Disease-Modifying Potential of STK-002 in Autosomal Dominant Optic Atrophy (ADOA) at the American Academy of Ophthalmology (AAO) 2026 Annual Meeting
Business Wire3 weeks ago
Funds containing STOK
Fund name | Fund size | $STOK weighting |
|---|---|---|
iShares Healthcare Innovation£DRDR | $1.3B | 0.16% |
iShares Healthcare Innovation€2B78 | $1.2B | 0.16% |
iShares Healthcare Innovation$HEAL | $1.3B | 0.16% |
iShares Ageing Population$AGED | $953M | 0.15% |
iShares Ageing Population€AGED | $903M | 0.15% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.